1,3-Dihydroxy-7-methoxy-2-(3-methylbut-2-enyl)xanthen-9-one

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡喃
• 英文名称: 1,3-Dihydroxy-7-methoxy-2-(3-methylbut-2-enyl)xanthen-9-one
• 化学式: C₁₉H₁₈O₅
• 分子量: 326.3
• InChiKey: PBHZGGZVVYPZKJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.7
• 重原子数：
  24
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.21
• 拓扑面积：
  76
• 氢给体数：
  2
• 氢受体数：
  5

文献信息

• USE OF XANTHONE DERIVATIVES AS A MEDICAMENT FOR CANCER
  申请人：Institut National De La Sante Et De La Recherche Medicale

  公开号：EP2262787A1

  公开（公告）日：2010-12-22
• Use of Xanthone Derivatives as a Medicament for Cancer
  申请人：Kolb Jean-Pierre

  公开号：US20110263694A1

  公开（公告）日：2011-10-27

  The invention relates to xanthone derivatives of formula (IA) or (IB) and their use for manufacturing a medicament for cancer, and in particular for chemotherapeutic resistant cancer. More particularly, the invention relates to compounds and compositions comprising such xanthone derivatives for the prevention and/or treatment for chronic leukemia and, for example, for chronic lymphocytic leukemia (CLL) or B-lymphoma.
• [EN] USE OF XANTHONE DERIVATIVES AS A MEDICAMENT FOR CANCER<br/>[FR] UTILISATION DE DÉRIVÉS DE XANTHONE EN TANT QUE MÉDICAMENT POUR LE CANCER
  申请人：INST NAT SANTE RECH MED

  公开号：WO2009124909A1

  公开（公告）日：2009-10-15

  The invention relates to xanthone derivatives of formula (IA) or (IB) and their use for manufacturing a medicament for cancer, and in particular for chemotherapeutic resistant cancer. More particularly, the invention relates to compounds and compositions comprising such xanthone derivatives for the prevention and/or treatment for chronic leukemia and, for example, for chronic lymphocytic leukemia (CLL) or B-lymphoma.